chr4-102510933-A-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001382625.1(NFKB1):c.-24A>G variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00744 in 1,285,530 control chromosomes in the GnomAD database, including 50 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.0049 ( 3 hom., cov: 32)
Exomes 𝑓: 0.0078 ( 47 hom. )
Consequence
NFKB1
NM_001382625.1 5_prime_UTR_premature_start_codon_gain
NM_001382625.1 5_prime_UTR_premature_start_codon_gain
Scores
1
1
11
Clinical Significance
Conservation
PhyloP100: 0.405
Genes affected
NFKB1 (HGNC:7794): (nuclear factor kappa B subunit 1) This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. NFKB is a critical regulator of the immediate-early response to viral infection. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Aug 2020]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.006662905).
BP6
Variant 4-102510933-A-G is Benign according to our data. Variant chr4-102510933-A-G is described in ClinVar as [Benign]. Clinvar id is 1675952.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00489 (744/152282) while in subpopulation NFE AF = 0.00853 (580/68030). AF 95% confidence interval is 0.00795. There are 3 homozygotes in GnomAd4. There are 346 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position FAILED quality control check.
BS2
High AC in GnomAd4 at 744 AD gene.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00489 AC: 744AN: 152164Hom.: 3 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
744
AN:
152164
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.00400 AC: 509AN: 127208 AF XY: 0.00396 show subpopulations
GnomAD2 exomes
AF:
AC:
509
AN:
127208
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00778 AC: 8817AN: 1133248Hom.: 47 Cov.: 29 AF XY: 0.00757 AC XY: 4207AN XY: 556046 show subpopulations
GnomAD4 exome
AF:
AC:
8817
AN:
1133248
Hom.:
Cov.:
29
AF XY:
AC XY:
4207
AN XY:
556046
Gnomad4 AFR exome
AF:
AC:
23
AN:
24226
Gnomad4 AMR exome
AF:
AC:
33
AN:
27938
Gnomad4 ASJ exome
AF:
AC:
2
AN:
15790
Gnomad4 EAS exome
AF:
AC:
0
AN:
12810
Gnomad4 SAS exome
AF:
AC:
151
AN:
75756
Gnomad4 FIN exome
AF:
AC:
66
AN:
12428
Gnomad4 NFE exome
AF:
AC:
8336
AN:
918618
Gnomad4 Remaining exome
AF:
AC:
203
AN:
41308
Heterozygous variant carriers
0
395
791
1186
1582
1977
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Exome Het
Exome Hom
Variant carriers
0
370
740
1110
1480
1850
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00489 AC: 744AN: 152282Hom.: 3 Cov.: 32 AF XY: 0.00465 AC XY: 346AN XY: 74460 show subpopulations
GnomAD4 genome
AF:
AC:
744
AN:
152282
Hom.:
Cov.:
32
AF XY:
AC XY:
346
AN XY:
74460
Gnomad4 AFR
AF:
AC:
0.00115501
AN:
0.00115501
Gnomad4 AMR
AF:
AC:
0.00202694
AN:
0.00202694
Gnomad4 ASJ
AF:
AC:
0
AN:
0
Gnomad4 EAS
AF:
AC:
0
AN:
0
Gnomad4 SAS
AF:
AC:
0.001868
AN:
0.001868
Gnomad4 FIN
AF:
AC:
0.0065033
AN:
0.0065033
Gnomad4 NFE
AF:
AC:
0.00852565
AN:
0.00852565
Gnomad4 OTH
AF:
AC:
0.00331126
AN:
0.00331126
Heterozygous variant carriers
0
37
74
112
149
186
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
37
ALSPAC
AF:
AC:
37
ExAC
AF:
AC:
28
Asia WGS
AF:
AC:
8
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jun 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
NFKB1: BS1, BS2 -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Uncertain
D;D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Pathogenic
D;D
MVP
ClinPred
T
GERP RS
Mutation Taster
=100/0
polymorphism
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at